Hemolytic Uremic Syndrome Medication

Updated: Oct 30, 2019
  • Author: Sombat Muengtaweepongsa, MD, MSc; Chief Editor: Amy Kao, MD  more...
  • Print
Medication

Medication Summary

Monoclonal antibodies (eg, eculizumab, ravulizumab) have been approved by the FDA for treatment of aHUS to inhibit complement-mediated thrombotic microangiopathy. These agents have been shown to reduced thrombocytopenia and hemolysis, and to improve renal function.

Next:

Monoclonal Antibodies

Class Summary

Monoclonal antibodies that target C5 result in preventing formation of complement complex C5b-9, thereby preventing RBC hemolysis.

Eculizumab (Soliris)

Indicated for treatment of aHUS to inhibit complement-mediated thrombotic microangiopathy; effectiveness based on the effects on thrombotic microangiopathy and renal function.

Ravulizumab (Ravulizumab-cwvz, Ultomiris)

Indicated for treatment of aHUS to inhibit complement-mediated thrombotic microangiopathy; effectiveness based on the effects on thrombotic microangiopathy and renal function.

Previous